XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

XLV, a broad healthcare ETF, offers lower costs (0.08% expense ratio) and higher dividend yield (1.60%) with more stability, while IBBQ, a concentrated biotech ETF, delivered stronger one-year returns (45.52% vs 26.79%) but with significantly higher volatility and drawdown risk. The choice depends on investor risk tolerance and investment objectives.

08/01/2026, 5:11 PM • The Motley Fool

Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031

Eli Lilly is positioned to become the first healthcare company to reach a $2 trillion market cap by 2031, requiring a 12.7% compound annual growth rate. The company's GLP-1 drug portfolio, led by tirzepatide (Mounjaro/Zepbound), is expected to drive strong revenue growth despite increasing competition. Additional growth catalysts include new product launches like Foundayo, pipeline candidates such as retatrutide, and AI-driven cost efficiencies across the organization.

08/01/2026, 4:17 PM • The Motley Fool

Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit?

The article compares two healthcare-focused ETFs: Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Healthcare ETF (IYH). FHLC is recommended as the better choice due to its significantly lower expense ratio (0.08% vs 0.38%), broader diversification with 334 holdings versus 100, and consistent outperformance across multiple time periods. Over 10 years, a $10,000 investment in FHLC would have yielded approximately $1,900 more than IYH.

08/01/2026, 1:28 PM • The Motley Fool

If You Invest $1,000 in the Vanguard High Dividend Yield ETF Right Now and Never Add Another Dollar, Here's What History Says It Could Deliver in 20 Years

The Vanguard High Dividend Yield ETF (VYM) has historically delivered a 9.32% annualized total return since 2006, outperforming non-dividend stocks. Based on historical performance, a $1,000 investment could grow to nearly $6,000 in 20 years through compounding, representing a ~500% total return. The ETF's broad diversification across 600+ stocks and low expense ratio make it suitable for long-term buy-and-hold investors seeking passive income.

08/01/2026, 10:30 AM • The Motley Fool

Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories and Johnson & Johnson are compared as healthcare investments for 2026. Abbott trades at lower valuations with expected 13% sales growth but faces litigation risks and slower growth in key products like FreeStyle Libre. Johnson & Johnson offers superior profitability and a robust pharmaceutical pipeline with 28 billion-dollar products, though it faces talc settlement costs and biosimilar competition. Abbott is recommended as the better buy due to stronger expected sales growth and lower valuation metrics.

07/31/2026, 3:29 PM • The Motley Fool

Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About

Johnson & Johnson is experiencing strong performance with stock up 28% YTD, driven by FDA clearance for its Ottava surgical robot, 64 consecutive years of dividend increases, and $100 billion revenue target. Most significantly, the company reached a proposed $5.5 billion settlement to resolve thousands of talc-related lawsuits, potentially eliminating a major legal risk. The company maintains resilience through diversified products and continues innovation with new drug approvals.

07/30/2026, 4:15 PM • The Motley Fool

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

The Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 423 holdings, while the Invesco Biotechnology & Genome ETF (PBE) provides focused biotech exposure with 31 holdings and higher growth potential. PBE delivered a stronger 40.88% one-year return but experienced greater volatility with a 37.84% maximum drawdown, while VHT returned 27.85% with lower risk. VHT suits conservative investors seeking steady, low-cost exposure, while PBE appeals to risk-tolerant investors chasing biotech innovation.

07/30/2026, 9:09 AM • The Motley Fool

Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stock

Eli Lilly is acquiring AtaiBeckley for $2.8 billion to expand beyond weight loss drugs into mental health treatments, including psychedelic-based therapies for treatment-resistant depression. This is the company's 12th acquisition this year and represents a strategic diversification effort, though the mental health market is smaller than the weight loss segment.

07/29/2026, 8:06 AM • The Motley Fool

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Johnson & Johnson maintains steady but modest revenue growth with strong dividend yields and diversified operations, while Eli Lilly demonstrates rapid revenue expansion driven by blockbuster diabetes and obesity drugs Mounjaro and Zepbound. Eli Lilly's revenue has nearly doubled over two years, narrowing the gap with J&J, though investors should monitor patent expiration risks and product concentration for both companies.

07/29/2026, 7:24 AM • The Motley Fool

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees

Vanguard Health Care ETF (VHT) outperforms VanEck Biotech ETF (BBH) with lower fees (0.09% vs 0.35%), higher dividend yield (1.6% vs 0.5%), and superior 5-year returns ($1,278 vs $1,004 on $1,000 invested). VHT offers broad diversification across 411 healthcare holdings, while BBH provides concentrated biotech exposure with 25 stocks and higher volatility.

07/28/2026, 8:20 AM • The Motley Fool

Ultrasonic Aspirator Market Size Projected to Reach USD 376.32 Million by 2035 | SNS Insider

The global ultrasonic aspirator market is valued at USD 194.03 million in 2025 and is projected to reach USD 376.32 million by 2035, growing at a CAGR of 6.87%. The U.S. market is expected to grow from USD 67.49 million to USD 118.90 million by 2035, driven by increasing adoption of advanced surgical technologies, rising neurosurgery procedures, and growing demand for minimally invasive surgeries. North America leads the market with 39.80% share, while Asia-Pacific registers the fastest growth at 8.83% CAGR.

07/28/2026, 6:49 AM • GlobeNewswire

After a Decade of Fighting Johnson & Johnson, Families Win a Historic $5.5 Billion Talc Settlement

Johnson & Johnson has agreed to an uncapped $5.5 billion settlement resolving claims from approximately 70,000 women and families who alleged the company's talc products, including Johnson's Baby Powder, contained asbestos and caused cancers such as ovarian cancer and mesothelioma. The settlement comes after decades of litigation, failed bankruptcy attempts, and mounting trial losses for J&J.

07/27/2026, 8:47 PM • GlobeNewswire

XLV vs FHLC: Which Healthcare ETF Fits Your Portfolio?

The State Street Health Care Select Sector SPDR ETF (XLV) and Fidelity MSCI Health Care Index ETF (FHLC) both offer low-cost healthcare exposure with identical 0.08% expense ratios. XLV focuses on 60 mega-cap healthcare stocks and has delivered stronger 5-year returns ($1,332 vs $1,276 on $1,000 invested), higher dividend yield (1.60% vs 1.30%), and greater liquidity with $41.7B in AUM. FHLC provides broader diversification with 365 holdings including mid and small-cap stocks. Over 10 years, both underperformed the S&P 500 significantly, with XLV returning 157% (9.9% CAGR) and FHLC returning 159% (10.0% CAGR) versus the S&P 500's 301% (14.9% CAGR).

07/27/2026, 8:35 AM • The Motley Fool

Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?

The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH), which focuses exclusively on 25 pharmaceutical companies with higher returns but higher costs, and State Street Health Care Select Sector SPDR ETF (XLV), which offers broader diversification across 60 healthcare positions with lower fees. While XLV outperforms over 10 years, PPH delivers superior 3-year and 5-year returns. The article recommends PPH for investors seeking recent performance gains, though XLV offers better cost efficiency and diversification.

07/26/2026, 1:01 PM • The Motley Fool

Does PayPal Have a Buyer?

Stripe and private equity firm Advent International have submitted a joint proposal to acquire PayPal for $60.50 per share, valuing the company at over $53 billion—a 28% premium. The deal would be structured as a 50/50 partnership to keep PayPal intact rather than break it up. While the offer highlights PayPal's fall from its $360 billion pandemic-era peak, analysts debate whether the price is sufficient and whether the partnership structure can work given inherent tensions between Stripe's growth ambitions and Advent's cash flow optimization goals.

07/24/2026, 9:16 PM • The Motley Fool